Neutropenic sepsis (CG151)
Fast, easy summary view of NICE guidance on 'neutropenic sepsis'
This guideline offers evidence-based advice on the prevention, identification and management of neutropenic sepsis in patients having anticancer treatment.
Neutropenic sepsis is caused by a condition known as neutropenia, in which the number of white blood cells (called neutrophils) in the blood is low. Neutrophils help the body to fight infection. People having anticancer treatment, particularly chemotherapy and more rarely radiotherapy, can be at risk of neutropenic sepsis. This is because these treatments can temporarily lower the number of neutrophils in the blood. Some anticancer treatments are more likely than others to cause a temporary period of neutropenia.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: neutropenic sepsis
This page was last updated: 17 February 2014
- Web format
- NICE Guideline (PDF)
- Full Guideline (PDF)
- CG151 Sepsis niwtropenig ymhlith pobl sy'n cael triniaeth gwrthganser: deall canllawiau NICE (fformat MS Word)
Information for the public
Following consultation with stakeholders this guideline has now been placed on the static list.
Implementation tools and resources
- Baseline assessment tool
- Clinical audit tools (folder)
- Costing report
- Costing template
- CG151 Neutropenic Sepsis: online educational tool
- CG151 Neutropenic sepsis: podcast
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guideline, contains the recommendations for health professionals and NHS bodies.
The published full clinical guideline for specialists with background, evidence, recommendations and methods used.